marketshareAI

Cizzle Biotechnology Holdings

CIZHealthcare
1.5500GBX
0.00%
Market Cap
6.14M
Volume
1.86k
0% of avg
P/E Ratio
EPS (TTM)
Beta
0.7
Day Range
0.0000p - 0.0000p
52 Week Range
0.0000p1.5500p2.6850p
1.5500p

Upcoming Events

31 July 2025
Next payment of US$250,000 expected from Cizzle Bio Inc licensing agreement
High Impact Event
September 2025
Second royalty payment of US$250,000 due to Cizzle Biotechnology
High Impact Event
January 21, 2026
Advanced minimum royalty of US$1 million previously due
High Impact Event
CIZ
NEUTRAL

Cizzle Biotechnology Announces Notice of Annual General Meeting

The diagnostics developer has announced the notice of its Annual General Meeting, which will be held on 30 June 2025.

CIZ
NEUTRAL

Cizzle Biotechnology Announces Holding(s) in Company

The biotechnology company has announced a change in its major shareholding structure.

CIZ
GOOD

Cizzle Biotechnology Raises £150,000 Through Convertible Loan Note

The diagnostics developer has raised £150,000 through a convertible loan note to support the rollout of its early cancer test in the UK and Europe, following a licensing deal in North America.

CIZ
GOOD

Cizzle Biotechnology Publishes 2024 Annual Results

The diagnostics developer publishes its annual results, providing limited details on its progress in developing an early lung cancer detection test.

CIZ
GOOD

Cizzle Biotechnology Secures First Caribbean Contract for CIZ1B Biomarker Test

The diagnostics developer has secured its first contract in the Caribbean for its CIZ1B biomarker test, triggering early royalty payments and signaling progress in the commercialization of its technology.

CIZ
NEUTRAL

Cizzle Biotechnology Launches New Corporate Website

The diagnostics developer has launched a new corporate website to provide information and updates to stakeholders.

CIZ
NEUTRAL

Cizzle Biotechnology Appoints New Non-Executive Director

The healthcare company has appointed a new non-executive director to strengthen its strategic and business capabilities.

CIZ
NEUTRAL

Cizzle Biotechnology Appoints First US Lab to Launch CIZ1B Cancer Test

The diagnostics developer has appointed a COLA accredited and CLIA certified lab in the US to launch its CIZ1B biomarker test for early-stage lung cancer detection.

CIZ
GOOD

Cizzle Biotechnology Appoints New Chief Scientific Officer, Advances Lung Cancer Biomarker Assay

The diagnostics developer has appointed a new Chief Scientific Officer and made progress on its lung cancer biomarker assay, positioning the company for potential growth.

CIZ
GOOD

Cizzle Biotechnology Expands North American Partnership to Include Caribbean

The diagnostics developer has expanded its North American partnership to include the Caribbean, securing early royalty payments and its first accredited laboratory partner as it advances towards product launch.